Lantheus (LNTH) M&A Announcement summary

Deal rationale and strategic fit

• Acquisition advances the company toward becoming a fully integrated radiopharmaceutical leader, expanding clinical and commercial manufacturing, and broadening the pipeline with clinical and preclinical theranostic pairs, including OCTEVY and PNT2003.

• Enhances capabilities across the radiopharmaceutical value chain, including Alzheimer's diagnostics, oncology therapeutics, and R&D expertise.

• Entry into new radiopharmaceutical markets with significant growth potential, leveraging existing expertise and diversifying the business.

• Internalizes advanced radioligand therapy manufacturing, reducing reliance on external partners and accelerating asset development.

• Adds a highly skilled team, supporting innovation and growth.

Financial terms and conditions

• $250 million upfront cash payment at closing, plus up to $752.5 million in development and sales milestone payments tied to OCTEVY and the pipeline.

• Transaction expected to close in the second half of 2025, subject to regulatory clearances and customary closing conditions.

• Deal is low single-digit percent dilutive to standalone EPS initially, with accretion expected about 18 months post-close when combined with recent acquisitions.

• Guidance for 2024 financials remains unchanged, with strong cash flow and balance sheet to support ongoing M&A.

Synergies and expected cost savings

• Internalizing scalable manufacturing infrastructure accelerates and de-risks critical development pathways, reducing reliance on outsourcing.

• Commercial and revenue synergies expected from launching a theranostic pair (OCTEVY and PNT2003) for neuroendocrine tumors.

• Shared commercialization and marketing costs for paired diagnostic and therapeutic products.

• Acquisition of a revenue-generating CDMO business enhances operational efficiency and supports long-term growth.